• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Markets
  3. / China

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
By ALEX FREW MCMILLAN
Jun 14, 2019 | 12:00 PM EDT
Stocks quotes in this article: BIDU, SNY, LLY, BMY, CTRYY, LGFRY

Thanks to a big IPO on the Hong Kong Stock Exchange, a Chinese couple have become China's richest husband-and-wife team.

The initial public offering of Hansoh Pharmaceutical Group, which closed up 37.3% on its debut on Friday, made Chairwoman Zhong Huijuan China's third-richest woman. Zhong's husband, Sun Piaoyang, is already worth $9.8 billion, according to Forbes. 

Together, Zhong and Sun have a $19.5 billion bank balance, which would make them wealthier than the Sackler family that owns OxyContin-maker Purdue Pharma, at $14 billion. They're also worth considerably more than Robin Li and Ma Dongmin, the husband-wife team who run Baidu  (BIDU) and previously China's top power couple, worth US$8.8 billion.

Zhong owns 68% of Hansoh, which now has a market capitalization of $14.2 billion in U.S. dollars. That values her stake at $9.7 billion. Among China's wealthiest women, only the property developers Yang Huiyan of Country Garden Holdings (CTRYY) and Longfor Properties (LGFRY) chairwoman Wu Yajun are worth more. Not bad for Zhong, who quit her job as a chemistry teacher to enter the drug business.

Zhong is riding the rapid growth in China's pharmaceutical industry, as the country concurrently gets richer and older. Revenue for Hansoh rose 24.8% in 2018, to $1.1 billion. Profits climbed 19.2%, to $275 million.

The company generated roughly $1 billion from the IPO. Singapore's sovereign wealth fund GIC is one of the cornerstone investors. Hansoh plans to use 45% of the IPO money to invest in research and development, with a quarter of that to build improved as well as new product lines. An additional 20% goes to sales promotions, and 10% will be kept as working capital.

Sun has led another drug company, Jiangsu Hengrui Medicine, since 1990. He has turned it from a state-owned company founded in 1970 into a highly profitable maker of medicine to combat cancer, with a small-molecule drug treatment for advanced gastric cancer, as well as cardiovascular disease, inflammation and central-nervous system conditions.

In May 2018, Forbes named Jiangsu Hengrui No. 64 out of the 100 most-innovative companies in the world. But that did not help Jiangsu Hengrui's market value. It was a torrid year for the stock, which lost 35.1% between May and the end of the year. The shares have advanced 39.4% so far in 2019, considerably bigger than Hansoh as a US$39.2 billion company.

Hansoh Pharmaceutical makes anti-infection and anti-tumor drugs, too, generating around half of sales from cancer treatments. It is far more accessible to overseas' investors, thanks to its Hong Kong listing, than Jiangsu Hengrui, which went public in 2000 with a listing in Shanghai.

Investors have clearly not been deterred by an investigation that the Chinese authorities have launched into potential kickbacks paid by drugmakers to doctors and hospital administrators, to get their drugs used.

Hansoh Pharmaceutical is on the list of 77 pharmaceutical companies released earlier this month that China's National Healthcare Security Administration and the Ministry of Finance are investigating. The Chinese arms of Sanofi (SNY) , Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) are also on the list.

There's suspicion that the embarrassment over the U.S. college admissions scandal may have prompted the investigation. The biggest bribe allegedly paid to college consult Rick Springer in the "Varsity Blues" case came from Zhao Tao, the chairman of Shandong Buchang Pharmaceutical, which is also on the list. Zhao says he was acting in a private capacity when he helped his daughter, "Molly" Zhao Yusi, get into Stanford University.

Springer allegedly paid a half million dollars to the Stanford University sailing team, and tried to get Molly Yao recruited to the team. He allegedly pocketed the rest of the $6.5 million paid by Zhao. The former Stanford sailing coach John Vandemoer reportedly pleaded guilty to racketeering, this week receiving a sentence of a day in prison, a $10,000 fine, and two years of supervised release. Stanford fired him after his plea.

It is the first conviction in the case, which has been an embarrassment in China, where aggressive parents will go to great lengths to push their children's education. The second-largest alleged payment, of $1.2 million to get a student into Yale, also came from a Chinese family.

But there are also problems within the Chinese pharmaceutical industry itself. Doctors say it is common practice to supplement your income by accepting "grey money" from drug companies to push their products.

A maker of traditional Chinese medicine, Kangmei Pharmaceutical, said in April that it had overstated its cash holdings by as much as $4.3 billion. That led to a regulatory probe, with China's stock watchdog finding the company used related parties to manipulate its shares.

Hansoh may come under a more-generic form of pressure as a result of the investigations. The Chinese government is on a long-term push to drive down the price of drugs. The government says it will instigate a second round of Group Purchase Organization price cuts for the national health service by September.

That would put pressure on margins at drugmakers. Those with proprietary treatments would likely fare better than those making generics. But Jiangsu Hengrui reportedly saw the price of its hypertension drug Irbesartan slashed 60% in a round of cuts in December.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Drug Approvals | Markets | Pharmaceuticals | China | Celebrity Interviews

More from China

Balloon Fallout, ODTE Options, The 'Wow' Week, Sloppy Earnings, Charting Bonds

Stephen Guilfoyle
Feb 6, 2023 7:20 AM EST

The latest way to gamble on market direction has become 'zero days to expiration' options or what Wall Street now refers to as ODTE options.

Balloon Blowup Creates Fallout for China Stock Rally

Alex Frew McMillan
Feb 6, 2023 6:14 AM EST

After rapid gains since the start of November, the rally in Hong Kong and China stocks has come unstuck in February as U.S.-China tensions flare again.

Japanese Leader Opens Parliament With Pledge to Spark Birth Rate

Alex Frew McMillan
Jan 23, 2023 8:45 AM EST

Similar to China's discouraging demographics released last week, Japan faces the big challenge of an ageing population that isn't replacing itself.

Welcoming the Water Rabbit at Lunar New Year

Alex Frew McMillan
Jan 20, 2023 6:30 AM EST

Many markets in East Asia are closed part or all of next week for the lunar holiday as China braces for the busiest travel period of the year.

As China Opens, ETFs Open Up Your Investing Options

Mark Abssy
Jan 17, 2023 3:13 PM EST

The flexibility of the ETF structure gives you several ways to either sidestep Chinese opportunities amid the emerging markets or play them as you see fit. Here are some options.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:22 AM EST REAL MONEY

    LIVE EVENT: Bruce Kamich and Todd Campbell Share Their Stock Market Insights

    This Monday, Feb. 6 at 12 p.m., our very own exper...
  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login